| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US23871209P | 2009-09-01 | 2009-09-01 | |
| US61/238,712 | 2009-09-01 |
| Publication Number | Publication Date |
|---|---|
| WO2011028794A2 WO2011028794A2 (en) | 2011-03-10 |
| WO2011028794A3true WO2011028794A3 (en) | 2011-07-21 |
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PCT/US2010/047520WO2011028794A2 (en) | 2009-09-01 | 2010-09-01 | Treatment of huntington's disease with cycloserine and an nmda receptor antagonist |
| Country | Link |
|---|---|
| WO (1) | WO2011028794A2 (en) |
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SI2753632T1 (en) | 2011-09-08 | 2023-08-31 | Sage Therapeutics, Inc. | Neuroactive steroids, their compositions and use |
| WO2014160480A1 (en) | 2013-03-13 | 2014-10-02 | Sage Therapeutics, Inc. | Neuroactive steroids and methods of use thereof |
| EP4306114A1 (en) | 2014-06-18 | 2024-01-17 | Sage Therapeutics, Inc. | Oxysterols and methods of use thereof |
| CN107405352A (en)* | 2014-10-07 | 2017-11-28 | 萨奇治疗股份有限公司 | Neurologically-active compounds and its application method |
| EP3319610A4 (en) | 2015-07-06 | 2019-03-06 | Sage Therapeutics, Inc. | Oxysterols and methods of use thereof |
| ES2884086T3 (en) | 2015-07-06 | 2021-12-10 | Sage Therapeutics Inc | Oxysteroles and their procedures for use |
| MX390302B (en) | 2015-07-06 | 2025-03-19 | Sage Therapeutics Inc | Oxysterols and methods of use thereof |
| JP7112331B2 (en) | 2016-04-01 | 2022-08-03 | セージ セラピューティクス， インコーポレイテッド | Oxysterols and their uses |
| US10752653B2 (en) | 2016-05-06 | 2020-08-25 | Sage Therapeutics, Inc. | Oxysterols and methods of use thereof |
| LT3481846T (en) | 2016-07-07 | 2021-08-25 | Sage Therapeutics, Inc. | 11-substituted 24-hydroxysterols for use in the treatment of nmda related conditions |
| BR112019006365A2 (en) | 2016-09-30 | 2019-08-06 | Sage Therapeutics Inc | c7 substituted oxisterols and methods of use thereof |
| TW202446399A (en) | 2016-10-18 | 2024-12-01 | 美商賽吉醫療公司 | Oxysterols and methods of use thereof |
| TWI815800B (en) | 2016-10-18 | 2023-09-21 | 美商賽吉醫療公司 | Oxysterols and methods of use thereof |
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20040157926A1 (en)* | 2003-02-06 | 2004-08-12 | Uriel Heresco-Levy | Pharmaceutical compositions for the treatment of movement disorders |
| US20060142241A1 (en)* | 2004-11-01 | 2006-06-29 | Yoo Seo H | Methods and compositions for reducing neurodegeneration in amyotrophic lateral sclerosis |
| WO2007006157A1 (en)* | 2005-07-14 | 2007-01-18 | The University Of British Columbia | Neuroprotective modulation of nmda receptor subtype activities |
| WO2008034815A1 (en)* | 2006-09-19 | 2008-03-27 | Laboratorios Del Dr. Esteve, S.A. | Combination of nmda- receptor ligand and a compound with 5-ht6 receptor affinity |
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20040157926A1 (en)* | 2003-02-06 | 2004-08-12 | Uriel Heresco-Levy | Pharmaceutical compositions for the treatment of movement disorders |
| US20060142241A1 (en)* | 2004-11-01 | 2006-06-29 | Yoo Seo H | Methods and compositions for reducing neurodegeneration in amyotrophic lateral sclerosis |
| WO2007006157A1 (en)* | 2005-07-14 | 2007-01-18 | The University Of British Columbia | Neuroprotective modulation of nmda receptor subtype activities |
| WO2008034815A1 (en)* | 2006-09-19 | 2008-03-27 | Laboratorios Del Dr. Esteve, S.A. | Combination of nmda- receptor ligand and a compound with 5-ht6 receptor affinity |
| Publication number | Publication date |
|---|---|
| WO2011028794A2 (en) | 2011-03-10 |
| Publication | Publication Date | Title |
|---|---|---|
| WO2011028794A3 (en) | Treatment of huntington's disease with cycloserine and an nmda receptor antagonist | |
| GB2443287B (en) | Methods, compositions and formulations for the treatment of thyroid eye disease | |
| IL217901B (en) | Use of an amount of laquninimod or a pharmaceutically acceptable salt thereof in the manufacture of a medicament for treating a human subject suffering from a bdnf-related disease | |
| EP1988852A4 (en) | Methods and devices for delivery of prosthetic heart valves and other prosthetics | |
| IL223783B (en) | Substituted 1-indole compound for use in the treatment of a disease or condition, a pharmaceutical composition comprising the compound and use of the compound for the preparation of a medicament | |
| PL2262476T3 (en) | Drug delivery to the anterior and posterior segments of the eye using eye drops. | |
| EP2007284A4 (en) | Devices and methods for treatment of tissue | |
| IL194820A0 (en) | Devices and methods for treatment of tissue | |
| MY173215A (en) | Acetylcysteine compositions and methods of use thereof | |
| EP4275752A3 (en) | Treatment of addiction and impulse-control disorders using pde7 inhibitors | |
| EP2019646A4 (en) | Method, device, and system for delivery of therapeutic agents to the eye | |
| WO2011109433A9 (en) | Tissue for prosthetic implants and grafts, and methods associated therewith | |
| IL216967B (en) | 17-hydroxy-17-pentafluoroethyl-estra-4,9(10)-dien-11-aryl derivatives and use thereof for the treatment of diseases | |
| GB2470818B (en) | Methods for administration and formulations for the treatment of regional adipose tissue | |
| WO2011146926A3 (en) | Systems and methods for treatment of sleep apnea | |
| GB201108964D0 (en) | Medicament and method of diagnosis | |
| WO2011044523A3 (en) | Compositions and methods for treating obesity | |
| NZ592049A (en) | Compositions and methods for the treatment of bowel diseases with granulated mesalamine | |
| EP2558104A4 (en) | Method and ophthalmic composition for treating retinal disease | |
| ZA201007005B (en) | Methods of diagnosing, preventing and treating bone mass diseases | |
| PT2603238E (en) | Methods and pharmaceutical compositions for the treatment of an ocular disease in a subject | |
| WO2010085799A9 (en) | Compositions and method for the treatment of parkinson's disease | |
| EP2716285A3 (en) | New method for identifying compounds useful for treating and/or preventing diseases associated with bone loss | |
| UA64530U (en) | method for treating hyperesthesia of solid teeth tissues in patients with gastroesofageal reflux disease | |
| WO2009029762A3 (en) | Farnesylamine inhibitors of the visual cycle |
| Date | Code | Title | Description |
|---|---|---|---|
| 121 | Ep: the epo has been informed by wipo that ep was designated in this application | Ref document number:10814422 Country of ref document:EP Kind code of ref document:A1 | |
| NENP | Non-entry into the national phase | Ref country code:DE | |
| 122 | Ep: pct application non-entry in european phase | Ref document number:10814422 Country of ref document:EP Kind code of ref document:A2 |